Rheumatology International

, Volume 31, Issue 1, pp 89–91

Churg-Strauss syndrome successfully treated with rituximab

Case Report

DOI: 10.1007/s00296-009-1146-6

Cite this article as:
Dønvik, K.K. & Omdal, R. Rheumatol Int (2011) 31: 89. doi:10.1007/s00296-009-1146-6


Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.


Vasculitis B cell depletion Eosinophilia Treatment 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Division of Internal Medicine, Department of RehabilitationStavanger University HospitalStavangerNorway
  2. 2.Division of Internal Medicine, Clinical Immunology UnitStavanger University HospitalStavangerNorway
  3. 3.Institute of Internal Medicine, Faculty of Medicine and OdontologyUniversity of BergenBergenNorway